rapid micro biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology and personal care products. the company's growth direct(tm) system detects contamination earlier, delivering compelling economic benefits to manufacturers while improving their quality process. the growth direct(tm) system is the first and only automated system that accelerates testing while fitting with current regulatory practices and addressing all key applications.
Company profile
Ticker
RPID
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
RAPID MICRO BIOSYSTEMS INC
SEC CIK
RPID stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
9 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
PRE 14A
Preliminary proxy
27 Mar 24
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
1 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
8-K
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter
10 Jan 24
424B3
Prospectus supplement
28 Dec 23
Transcripts
RPID
Earnings call transcript
2023 Q4
1 Mar 24
RPID
Earnings call transcript
2023 Q3
3 Nov 23
RPID
Earnings call transcript
2023 Q2
4 Aug 23
RPID
Earnings call transcript
2023 Q1
5 May 23
RPID
Earnings call transcript
2022 Q4
3 Mar 23
RPID
Earnings call transcript
2022 Q3
10 Nov 22
RPID
Earnings call transcript
2022 Q2
13 Aug 22
RPID
Earnings call transcript
2022 Q1
14 May 22
RPID
Earnings call transcript
2021 Q4
4 Mar 22
RPID
Earnings call transcript
2021 Q2
26 Aug 21
Latest ownership filings
4
John J. Addington Wilson
12 Mar 24
4
VICTORIA VEZINA
12 Mar 24
4
SEAN M WIRTJES
12 Mar 24
4
Robert G. Jr. Spignesi
12 Mar 24
4
John J. Addington Wilson
14 Feb 24
4
VICTORIA VEZINA
14 Feb 24
4
SEAN M WIRTJES
14 Feb 24
4
Robert G. Jr. Spignesi
14 Feb 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
14 Feb 24
4
SEAN M WIRTJES
8 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.07 mm | 24.07 mm | 24.07 mm | 24.07 mm | 24.07 mm | 24.07 mm |
Cash burn (monthly) | 1.63 mm | 170.50 k | 4.82 mm | 5.14 mm | 3.24 mm | 3.94 mm |
Cash used (since last report) | 11.26 mm | 1.18 mm | 33.23 mm | 35.44 mm | 22.33 mm | 27.16 mm |
Cash remaining | 12.81 mm | 22.89 mm | -9.16 mm | -11.37 mm | 1.74 mm | -3.09 mm |
Runway (months of cash) | 7.9 | 134.3 | -1.9 | -2.2 | 0.5 | -0.8 |
Institutional ownership, Q3 2023
98.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 4 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 23.23 bn |
Total shares | 37.01 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Investors | 8.43 mm | $9.11 bn |
Bain Capital Life Sciences Fund | 7.65 mm | $81.41 mm |
Kennedy Lewis Management | 4.94 mm | $5.34 bn |
Longitude Capital Partners II | 4.04 mm | $0.00 |
Endeavour Medtech Growth II | 2.24 mm | $23.87 mm |
Colony Harvest | 1.62 mm | $0.00 |
JPM JPMorgan Chase & Co. | 1.43 mm | $1.55 bn |
Glenview Capital Management | 1.32 mm | $1.42 bn |
ABG-WTT Global Life Science Capital Partners GP | 1.04 mm | $1.12 bn |
BLK Blackrock | 1.02 mm | $1.10 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Robert G. Jr. Spignesi | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.981 | 10,323 | 10.13 k | 468,824 |
11 Mar 24 | Victoria Vezina | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.981 | 5,435 | 5.33 k | 112,608 |
11 Mar 24 | Sean M Wirtjes | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.981 | 7,454 | 7.31 k | 325,403 |
11 Mar 24 | John J. Addington Wilson | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.981 | 9,569 | 9.39 k | 188,738 |
12 Feb 24 | John J. Addington Wilson | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.96 | 5,809 | 5.58 k | 198,307 |
Press releases
Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024
18 Apr 24
Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024
19 Mar 24
Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum
12 Mar 24
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 Mar 24
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
1 Mar 24